Scaffold-free parathyroid tissue engineering using tonsil-derived mesenchymal stem cells

Yoon Shin Park, Ji Young Hwang, Yesl Jun, Yoon Mi Jin, Gyungah Kim, Ha Yeong Kim, Han Su Kim, Sang Hoon Lee, Inho Jo

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

To restore damaged parathyroid function, parathyroid tissue engineering is the best option. Previously, we reported that differentiated tonsil-derived mesenchymal stem cells (dTMSC) restore in vivo parathyroid function, but only if they are embedded in a scaffold. Because of the limited biocompatibility of Matrigel, however, here we developed a more clinically applicable, scaffold-free parathyroid regeneration system. Scaffold-free dTMSC spheroids were engineered in concave microwell plates made of polydimethylsiloxane in control culture medium for the first 7 days and differentiation medium (containing activin A and sonic hedgehog) for next 7 days. The size of dTMSC spheroids showed a gradual and significant decrease up to day 5, whereafter it decreased much less. Cells in dTMSC spheroids were highly viable (>80%). They expressed high levels of intact parathyroid hormone (iPTH), the parathyroid secretory protein 1, and cell adhesion molecule, N-cadherin. Furthermore, dTMSC spheroids-implanted parathyroidectomized (PTX) rats revealed higher survival rates (50%) over a 3-month period with physiological levels of both serum iPTH (57.7-128.2 pg/mL) and ionized calcium (0.70-1.15 mmol/L), compared with PTX rats treated with either vehicle or undifferentiated TMSC spheroids. This is the first report of a scaffold-free, human stem cell-based parathyroid tissue engineering and represents a more clinically feasible strategy for hypoparathyroidism treatment than those requiring scaffolds. Statement of Significance Herein, we have for the first time developed a scaffold-free parathyroid tissue spheroids using differentiated tonsil-derived mesenchymal stem cells (dTMSC) to restore in vivo parathyroid cell functions. This new strategy is effective, even for long periods (3 months), and is thus likely to be more feasible in clinic for hypoparathyroidism treatment. Development of TMSC spheroids may also provide a convenient and efficient scaffold-free platform for researchers investigating conditions involving abnormal calcium homeostasis, such as osteoporosis.

Original languageEnglish
Pages (from-to)215-227
Number of pages13
JournalActa Biomaterialia
Volume35
DOIs
Publication statusPublished - 2016 Apr 15

Fingerprint

Palatine Tonsil
Tissue Engineering
Scaffolds (biology)
Stem cells
Mesenchymal Stromal Cells
Tissue engineering
Scaffolds
Hypoparathyroidism
Parathyroid Hormone
Rats
Calcium
Chromogranin A
Hedgehogs
Cell Adhesion Molecules
Cadherins
Cell adhesion
Osteoporosis
Polydimethylsiloxane
Culture Media
Regeneration

Keywords

  • Hypoparathyroidism
  • N-cadherin
  • Parathyroid hormone
  • Spheroid
  • Tonsil-derived mesenchymal stem cells

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Biotechnology
  • Biochemistry
  • Molecular Biology

Cite this

Park, Y. S., Hwang, J. Y., Jun, Y., Jin, Y. M., Kim, G., Kim, H. Y., ... Jo, I. (2016). Scaffold-free parathyroid tissue engineering using tonsil-derived mesenchymal stem cells. Acta Biomaterialia, 35, 215-227. https://doi.org/10.1016/j.actbio.2016.03.003

Scaffold-free parathyroid tissue engineering using tonsil-derived mesenchymal stem cells. / Park, Yoon Shin; Hwang, Ji Young; Jun, Yesl; Jin, Yoon Mi; Kim, Gyungah; Kim, Ha Yeong; Kim, Han Su; Lee, Sang Hoon; Jo, Inho.

In: Acta Biomaterialia, Vol. 35, 15.04.2016, p. 215-227.

Research output: Contribution to journalArticle

Park, Yoon Shin ; Hwang, Ji Young ; Jun, Yesl ; Jin, Yoon Mi ; Kim, Gyungah ; Kim, Ha Yeong ; Kim, Han Su ; Lee, Sang Hoon ; Jo, Inho. / Scaffold-free parathyroid tissue engineering using tonsil-derived mesenchymal stem cells. In: Acta Biomaterialia. 2016 ; Vol. 35. pp. 215-227.
@article{410300523a4547e8ae7cc74d0fb66b73,
title = "Scaffold-free parathyroid tissue engineering using tonsil-derived mesenchymal stem cells",
abstract = "To restore damaged parathyroid function, parathyroid tissue engineering is the best option. Previously, we reported that differentiated tonsil-derived mesenchymal stem cells (dTMSC) restore in vivo parathyroid function, but only if they are embedded in a scaffold. Because of the limited biocompatibility of Matrigel, however, here we developed a more clinically applicable, scaffold-free parathyroid regeneration system. Scaffold-free dTMSC spheroids were engineered in concave microwell plates made of polydimethylsiloxane in control culture medium for the first 7 days and differentiation medium (containing activin A and sonic hedgehog) for next 7 days. The size of dTMSC spheroids showed a gradual and significant decrease up to day 5, whereafter it decreased much less. Cells in dTMSC spheroids were highly viable (>80{\%}). They expressed high levels of intact parathyroid hormone (iPTH), the parathyroid secretory protein 1, and cell adhesion molecule, N-cadherin. Furthermore, dTMSC spheroids-implanted parathyroidectomized (PTX) rats revealed higher survival rates (50{\%}) over a 3-month period with physiological levels of both serum iPTH (57.7-128.2 pg/mL) and ionized calcium (0.70-1.15 mmol/L), compared with PTX rats treated with either vehicle or undifferentiated TMSC spheroids. This is the first report of a scaffold-free, human stem cell-based parathyroid tissue engineering and represents a more clinically feasible strategy for hypoparathyroidism treatment than those requiring scaffolds. Statement of Significance Herein, we have for the first time developed a scaffold-free parathyroid tissue spheroids using differentiated tonsil-derived mesenchymal stem cells (dTMSC) to restore in vivo parathyroid cell functions. This new strategy is effective, even for long periods (3 months), and is thus likely to be more feasible in clinic for hypoparathyroidism treatment. Development of TMSC spheroids may also provide a convenient and efficient scaffold-free platform for researchers investigating conditions involving abnormal calcium homeostasis, such as osteoporosis.",
keywords = "Hypoparathyroidism, N-cadherin, Parathyroid hormone, Spheroid, Tonsil-derived mesenchymal stem cells",
author = "Park, {Yoon Shin} and Hwang, {Ji Young} and Yesl Jun and Jin, {Yoon Mi} and Gyungah Kim and Kim, {Ha Yeong} and Kim, {Han Su} and Lee, {Sang Hoon} and Inho Jo",
year = "2016",
month = "4",
day = "15",
doi = "10.1016/j.actbio.2016.03.003",
language = "English",
volume = "35",
pages = "215--227",
journal = "Acta Biomaterialia",
issn = "1742-7061",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Scaffold-free parathyroid tissue engineering using tonsil-derived mesenchymal stem cells

AU - Park, Yoon Shin

AU - Hwang, Ji Young

AU - Jun, Yesl

AU - Jin, Yoon Mi

AU - Kim, Gyungah

AU - Kim, Ha Yeong

AU - Kim, Han Su

AU - Lee, Sang Hoon

AU - Jo, Inho

PY - 2016/4/15

Y1 - 2016/4/15

N2 - To restore damaged parathyroid function, parathyroid tissue engineering is the best option. Previously, we reported that differentiated tonsil-derived mesenchymal stem cells (dTMSC) restore in vivo parathyroid function, but only if they are embedded in a scaffold. Because of the limited biocompatibility of Matrigel, however, here we developed a more clinically applicable, scaffold-free parathyroid regeneration system. Scaffold-free dTMSC spheroids were engineered in concave microwell plates made of polydimethylsiloxane in control culture medium for the first 7 days and differentiation medium (containing activin A and sonic hedgehog) for next 7 days. The size of dTMSC spheroids showed a gradual and significant decrease up to day 5, whereafter it decreased much less. Cells in dTMSC spheroids were highly viable (>80%). They expressed high levels of intact parathyroid hormone (iPTH), the parathyroid secretory protein 1, and cell adhesion molecule, N-cadherin. Furthermore, dTMSC spheroids-implanted parathyroidectomized (PTX) rats revealed higher survival rates (50%) over a 3-month period with physiological levels of both serum iPTH (57.7-128.2 pg/mL) and ionized calcium (0.70-1.15 mmol/L), compared with PTX rats treated with either vehicle or undifferentiated TMSC spheroids. This is the first report of a scaffold-free, human stem cell-based parathyroid tissue engineering and represents a more clinically feasible strategy for hypoparathyroidism treatment than those requiring scaffolds. Statement of Significance Herein, we have for the first time developed a scaffold-free parathyroid tissue spheroids using differentiated tonsil-derived mesenchymal stem cells (dTMSC) to restore in vivo parathyroid cell functions. This new strategy is effective, even for long periods (3 months), and is thus likely to be more feasible in clinic for hypoparathyroidism treatment. Development of TMSC spheroids may also provide a convenient and efficient scaffold-free platform for researchers investigating conditions involving abnormal calcium homeostasis, such as osteoporosis.

AB - To restore damaged parathyroid function, parathyroid tissue engineering is the best option. Previously, we reported that differentiated tonsil-derived mesenchymal stem cells (dTMSC) restore in vivo parathyroid function, but only if they are embedded in a scaffold. Because of the limited biocompatibility of Matrigel, however, here we developed a more clinically applicable, scaffold-free parathyroid regeneration system. Scaffold-free dTMSC spheroids were engineered in concave microwell plates made of polydimethylsiloxane in control culture medium for the first 7 days and differentiation medium (containing activin A and sonic hedgehog) for next 7 days. The size of dTMSC spheroids showed a gradual and significant decrease up to day 5, whereafter it decreased much less. Cells in dTMSC spheroids were highly viable (>80%). They expressed high levels of intact parathyroid hormone (iPTH), the parathyroid secretory protein 1, and cell adhesion molecule, N-cadherin. Furthermore, dTMSC spheroids-implanted parathyroidectomized (PTX) rats revealed higher survival rates (50%) over a 3-month period with physiological levels of both serum iPTH (57.7-128.2 pg/mL) and ionized calcium (0.70-1.15 mmol/L), compared with PTX rats treated with either vehicle or undifferentiated TMSC spheroids. This is the first report of a scaffold-free, human stem cell-based parathyroid tissue engineering and represents a more clinically feasible strategy for hypoparathyroidism treatment than those requiring scaffolds. Statement of Significance Herein, we have for the first time developed a scaffold-free parathyroid tissue spheroids using differentiated tonsil-derived mesenchymal stem cells (dTMSC) to restore in vivo parathyroid cell functions. This new strategy is effective, even for long periods (3 months), and is thus likely to be more feasible in clinic for hypoparathyroidism treatment. Development of TMSC spheroids may also provide a convenient and efficient scaffold-free platform for researchers investigating conditions involving abnormal calcium homeostasis, such as osteoporosis.

KW - Hypoparathyroidism

KW - N-cadherin

KW - Parathyroid hormone

KW - Spheroid

KW - Tonsil-derived mesenchymal stem cells

UR - http://www.scopus.com/inward/record.url?scp=84960862062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960862062&partnerID=8YFLogxK

U2 - 10.1016/j.actbio.2016.03.003

DO - 10.1016/j.actbio.2016.03.003

M3 - Article

C2 - 26945633

AN - SCOPUS:84960862062

VL - 35

SP - 215

EP - 227

JO - Acta Biomaterialia

JF - Acta Biomaterialia

SN - 1742-7061

ER -